February 8, 2019
A key health ministry committee will discuss whether to recommend a batch of new drugs including Pfizer’s sakigake -designated Vyndaqel (tafamidis) and Shionogi’s pediatric ADHD treatment lisdexamfetamine dimesylate, known as Vyvanse overseas, on February 21. If given the nod, they...read more